Scaling AI Drug Discovery With NYB.AI and Nebius

NYB.AI is using Nebius GPU infrastructure to speed up AI-driven molecular discovery — cutting workflows that once took months down to days or hours. NYB.AI, a Singapore-based AI drug discovery startup spun out from Nanyang Technological University, is building AI models to accelerate molecular discovery across pharmaceuticals, food, cosmetics, and other science-driven industries. Hear from Duy Trieu, CTO of NYB.AI, about how the company's drug-target interaction graph neural network helps predict how compounds interact with proteins in the body, reducing the time and cost of identifying promising candidates before wet-lab validation. He shares how NYB.AI worked with Nebius to scale compute-intensive molecular discovery workflows. With reliable GPU infrastructure from Nebius, large-scale parallel inference, and hands-on technical support, the team is building faster feedback loops between AI models and scientists in the lab. Explore more customer stories: https://nebius.com/customer-stories